18:31 , Aug 31, 2018 |  BC Week In Review  |  Financial News

Arvinas looking to raise $100M in IPO

Protein degradation company Arvinas LLC (New Haven, Conn.) filed to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, Citigroup and Piper Jaffray. Arvinas is developing small molecules based on its...
19:59 , Aug 30, 2018 |  BC Extra  |  Financial News

Arvinas looking to raise $100M in IPO

Protein degradation company Arvinas LLC (New Haven, Conn.) filed to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, Citigroup and Piper Jaffray. Arvinas is developing small molecules based on its...
19:51 , Aug 10, 2018 |  BioCentury  |  Finance

Sound story

Preclinical data supporting Akouos Inc.’s hearing loss program convinced 5AM Ventures to re-up for a $50 million series A round, and those funds plus additions to the Akouos team have the company poised to take...
18:40 , Aug 10, 2018 |  BC Week In Review  |  Financial News

Hearing loss play Akouos grabs $50M series A

Akouos Inc. (Boston, Mass.) raised $50 million on Aug. 7 in a series A round co-led by existing investors 5AM Ventures and New Enterprise Associates. Partners Innovation Fund and new investors Sofinnova Ventures, RA Capital...
11:03 , Aug 7, 2018 |  BC Extra  |  Financial News

Hearing loss play Akouos grabs $50M series A

Akouos Inc. (Boston, Mass.) raised $50 million in a series A round co-led by existing investors 5AM Ventures and New Enterprise Associates. Partners Innovation Fund and new investors Sofinnova Ventures, RA Capital Management and Novartis...
21:18 , Jun 29, 2018 |  BC Week In Review  |  Financial News

Crinetics proposes $86.3M IPO

Endocrine disease company Crinetics Pharmaceuticals Inc. (San Diego, Calif.) proposed on June 22 to raise up to $86.3 million in an IPO on NASDAQ underwritten by J.P. Morgan, Leerink and Piper Jaffray. In March, Crinetics raised...
15:02 , Jun 29, 2018 |  BC Week In Review  |  Financial News

Sofinnova Partners, 5AM lead £28 million NodThera series A

Inflammation company NodThera Ltd. (Cambridge, U.K.) raised £28 million ($37 million) in a tranched series A led by Sofinnova Partners and 5AM Ventures. Epidarex Capital, which founded NodThera in 2016, and F-Prime Capital Partners also...
13:22 , Jun 29, 2018 |  BioCentury  |  Finance

Nailing down NLRP3

The next-generation chemistry behind its NLRP3 inhibitors enabled inflammasome play NodThera Ltd. to close a £28 million ($37 million) series A round led by Sofinnova Partners and 5AM Ventures. F-Prime Capital Partners and founding investor...
07:11 , Jun 25, 2018 |  BC Extra  |  Financial News

Sofinnova Partners, 5AM lead £28 million NodThera series A

Inflammation company NodThera Ltd. (Cambridge, U.K.) raised £28 million ($37 million) in a tranched series A led by Sofinnova Partners and 5AM Ventures. Epidarex Capital, which founded NodThera in 2016, and F-Prime Capital Partners also...
22:11 , Jun 22, 2018 |  BC Extra  |  Financial News

Crinetics proposes $86.3M IPO

Endocrine disease company Crinetics Pharmaceuticals Inc. (San Diego, Calif.) proposed to raise up to $86.3 million in an IPO on NASDAQ underwritten by J.P. Morgan, Leerink and Piper Jaffray. In March, Crinetics raised a $63.5 million...